A Prospective Randomized, Multi-center study to assess the Safety and Efficacy of Mucosta (Rebamipide), in combination with Omeprazole as adjuvant therapy in Gastric Ulcer Patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
129
open label, oral route, Rebamipide, 100mg tablet t.i.d and Omeprazole 20 mg tablet B.I.D. for 8 weeks
open label,oral route, Omeprazole 20mg tablet, B. I.D.; alone, for 8 weeks
Abbasi Shaheed Hospital
Karachi, Pakistan
Dow University of Health Sciences
Karachi, Pakistan
Dr. Ziauddin University Hospital
Karachi, Pakistan
Healing rates for gastric ulcer patients via endoscopic examination
Time frame: 8 weeks treatment plus 4 weeks follow-up
Improvement or absence of gastric ulcer associated symptoms
Improvement or absence of gastric ulcer associated symptoms, i.e. pain, burning, etc.
Time frame: 8 weeks treatment plus 4 weeks follow-up
To determine and compare the Safety profile in both the treatment arms.
Time frame: 8 weeks treatment plus 4 weeks follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.